Home Pharmacognosy Can antibiotics treat human diseases in addition to

Can antibiotics treat human diseases in addition to


image: An antibiotic (green), bound in the human-type yeast ribosome (gray), allows the synthesis of some proteins (shown in orange, purple and blue) but not others (dark green).
seen Following

Credit: Maxim Svetlov / UIC

Antibiotics used to treat common bacterial infections, like pneumonia and sinusitis, can also be used to treat human illnesses, like cancer, according to researchers at the University of Illinois at Chicago. Theoretically, at least.

As shown in a new Nature Communication study, the UIC College of Pharmacy team showed in laboratory experiments that eukaryotic ribosomes can be modified to respond to antibiotics in the same way as prokaryotic ribosomes.

Fungi, plants and animals – like humans – are eukaryotes; they are made up of cells with a clearly defined nucleus. Bacteria, on the other hand, are prokaryotes. They are made up of cells that do not have a nucleus and have different structure, size and properties. The ribosomes of eukaryotic and prokaryotic cells, which are responsible for synthesizing proteins necessary for cell growth and reproduction, are also different.

“Some antibiotics, used to treat bacterial infections, work in interesting ways. They bind to the ribosome of bacterial cells and very selectively inhibit protein synthesis. Some proteins can be made, but others are not,” he said. said Alexander Mankin, the Alexander Neyfakh Professor of Medicinal Chemistry and Pharmacognosy at UIC College of Pharmacy and lead author of the study. “Without these proteins being made, bacteria die.”

When people use antibiotics to treat an infection, the patient’s cells are not affected because the drugs are not designed to bind to ribosomes of different shapes than eukaryotic cells.

“Because there are many human diseases caused by the expression of unwanted proteins – this is common in many types of cancer or neurodegenerative diseases, for example – we wanted to know if it would be possible to use an antibiotic. to stop a human cell from making unwanted proteins, and only unwanted proteins, ”Mankin said.

To answer this question, Mankin and the study’s first author, Maxim Svetlov, an assistant research professor in the Department of Pharmaceutical Sciences, turned to yeast, a eukaryote with cells similar to human cells.

The research team, which included partners from Germany and Switzerland, did a “cool thing,” Mankin said. “We designed the yeast ribosome to look more like bacteria.”

Mankin and Svetlov’s team used biochemistry and fine genetics to alter over 7,000 nucleotides in yeast ribosomal RNA, which was enough to make a macrolide antibiotic – a common class of antibiotics that work by binding to bacterial ribosomes – acts on the yeast ribosome. Using this yeast model, the researchers applied genomic profiling and high-resolution structural analysis to understand how each protein in the cell is synthesized and how the macrolide interacts with the yeast ribosome.

“Thanks to this analysis, we understood that depending on the specific genetic signature of a protein – the presence of a” good “or” bad “sequence – the macrolide can stop its production on the ribosome. eukaryotic or not, ”Mankin said. “This has shown us, conceptually, that antibiotics can be used to selectively inhibit protein synthesis in human cells and used to treat human disorders caused by ‘bad’ proteins.”

The experiments of UIC researchers constitute a platform for future studies. “Now that we know the concepts work, we can search for antibiotics that can bind to unmodified eukaryotic ribosomes and optimize them to only inhibit proteins that are bad for humans,” Mankin said.


Additional study co-authors are Dorota Klepacki and Nora Vázquez-Laslop from UIC; Timm Koller and Daniel Wilson from the University of Hamburg; Sezen Meydan and Nicholas Guydosh of the National Institutes of Health; and Norbert Polacek and Vaishnavi Shankar from the University of Bern.

This work was supported by grants from the National Institutes of Health (R35 GM127134, DK075132, 1FI2GM137845), the German Research Foundation (WI3285 / 6-1) and the Swiss National Science Foundation (31003A_166527).

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.


Please enter your comment!
Please enter your name here